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Schizophrenia: do men and women suffer from the same disease?
Heinz Häfner
ABSTRACT
This article reviews the literature on normal brain development and behavioural development in men and women as
well as on aetiological risk factors for schizophrenia, such as pre-, peri- and postnatal complications.
The male-female comparisons of age and type of onset, symptomatology, course and outcome were based on a
population-based sample of 232 first illness episodes – the ABC Schizophrenia Study sample. The probands were
assessed using the IRAOS interview and other instruments retrospectively at first admission and prospectively at six
cross sections over five years after first contact. A representative subsample of 130 first admissions or 115 first
illness episodes were compared with 130 controls, matched by age, sex and area of residence.
Women, 3 to 4 years older than men at illness onset, showed a second peak of onsets in age group 45 to 50 years. After
animal experiments and a controlled clinical study this finding was explained by a protective effect of oestrogen
persisting until menopause. The underlying neurobiological mechanism consisted in a sensitivity reducing effect of
oestrogen on D2 receptors in the brain. The effect of oestrogen, meanwhile confirmed in randomised control trials,
also includes genomic effects as well as interactions with free-radical detoxifying systems, thus demonstrating the
neuroprotective capabilities of oestrogen.
Postmenopausal schizophrenia was more frequent and more severe in women. Men fell ill more frequently and more
severely at young age and less frequently and more mildly later in life. Illness course, too, was more unfavourable in
postmenopausal women than in their male peers.
The protective effect of oestrogen in women depended on the degree of their predisposition to the illness: the higher
the familial load for schizophrenia, the weaker the protection by oestrogen. The more favourable illness course in
premenopausal women resulted from their higher level of social development at illness onset – determined by their
higher age at onset – and from their socially more adaptive behaviour. The illness behaviour of young men showed a
significant excess of socially negative behaviours with an unfavourable impact on their early illness course. In
contrast, older men were socially better adjusted. With genetic and morphological findings considered the subtypes
of schizophrenia did not differ between men and women.
Gender differences in symptomatology and course of schizophrenia obviously are not explained by differences in the
disease process. They seem to be determined by a complex pattern of interaction between disease variables, hormonal
and behavioural differences and their consequences for age at onset and illness course.
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Introduction
Nearly one hundred years ago Kraepelin (1909-
1915) pointed to women’s several years higher age at
first admission for dementia praecox compared to men’s.
Since then the finding has been replicated in more than
50 studies (for a review see Angermeyer and Kühn,
1988). Discrepant findings have been reported mainly
from India (Murthy et al., 1998; Gangadhar et al., 2002).
But systematic empirical research into various aspects
of gender differences in schizophrenia has been pursued
for only about 15 years. According to Moldin (2000)
robust gender differences in major disease variables
“may have important implications both in future
research on the pathophysiology and aetiology of
schizophrenia and in clinical practice”.
Gender differences in schizophrenia can be studied
in various domains:
1. Diagnoses, types of onset, subtypes of the
disorder and symptoms.
2. Lifetime risk for psychosis and distribution of
onset over the life-cycle.
3. Distant (genetic, pre- and perinatal) and proxy
(antecedent) risk factors.
4. Premorbid functioning, determinants and
consequences of the gender difference in age
at onset.
5. Gender-specific illness behaviour versus
illness-specific deficits and symptoms.
6. Course and outcome.
7. Brain development, structure and functioning.
8. Treatment and care.
I will discuss these eight domains, as far as we
have informative data available.
Proceeding particularly from the sex difference
in age at first admission – a fairly robust finding reported
from allover the world – in 1986 we launched a
systematic study into sex differences and other aspects
of schizophrenia. The study has been funded
continuously for 16 years by grants from the German
Research Association (DFG). We hoped that studying
this robust variable would yield us information on causal
determinants of the first emergence of the disorder and,
hence, some insight into pathophysiological processes
underlying its symptomatology and course. For this
reason, the study was designed as consisting of three
levels – epidemiological, clinical and biological. As the
study progressed, new hypotheses were continuously
formulated on the basis of the results gained.
I am particularly happy to be able to present results
from this study at the invitation of my longtime research
partner and friend Wagner Gattaz. It was with him that
we planned the biological part, especially the animal
experiments, of the study.
A large part of our analyses will be based on a
population-based sample of 232 first illness episodes
of a broad diagnosis of schizophrenia (ICD-9: 295,
297, 298.3), =84 % of first admissions from a semi-
urban, semi-rural German population of about 1.5
million. The patients, aged 12 to 59 years, were
assessed with the PSE (Wing et al. 1974), the SANS
(Andreasen, 1983), the PIRS (Biehl et al., 1989), the
DAS (World Health Organization 1988, Jung et al.
1989) immediately upon hospitalisation in the first
psychotic episode. Individual premorbid development,
onset and early course were assessed retrospectively
using the IRAOS interview (Häfner et al., 1992, 1999)
4 to 6 weeks later in order to keep memory distortions
to a minimum. A subsample of 130 cases was
compared with the corresponding data for 130
“healthy” population controls and 130 first-admission
cases with a diagnosis of a depressive episode, both
matched for age, sex and area of residence (Figure 1).
Figure 1 ABC Schizophrenia Study: design for early and medium-term course of schizophrenia spectrum disorder (ICD 295, 297, 298.3,
298.4) from onset to 5 years after first admission.
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Illness course from first admission on was
assessed prospectively over 5 years in a subsample of
115 first episodes of schizophrenia using the same
instruments and additonally the FU-HSD (WHO, 1980)
and over 15 years in another representative sample of
70 first admissions.
Domain 1: diagnoses, subtypes, symptoms, type of
course
Most studies report a greater frequency of positive
and affective symptoms for women and more negative
symptoms and insidious types of onset for men (Castle
et al., 1993; Castle, 1999). But there are also several
reports of men showing a greater frequency of positive
symptoms compared with women (Goldstein and Link,
1988; Bardenstein and McGlashan, 1990; Lewis, 1992).
Still other studies have failed to find comparable gender
differences (Fennig et al., 1995; Kendler and Walsh,
1995; Moldin, 2000). For testing these diverging results
we compared diagnoses, subtypes, symptoms and
types of onset or early course at the same stages of
illness: (1) in the first psychotic episode with maximum
symptom presentation, (2) at illness onset with
minimum symptom presentation and (3) cumulatively
in the early course from onset to first admission.
As shown in table 1, significant differences were
found in none of the clinical or the operationalised
diagnoses, scores or syndromes in the psychotic
episode. Nor did the 10 most frequent initial symptoms,
i.e. at illness onset – defined by the emergence of the
first sign of mental disorder – show significant gender
differences, except one item, which was significantly
more frequent in women: worrying. But the frequency
of this item is specific to female gender rather than to
the disorder (Häfner et al., 1995) (Table 2).
The results of comparative neuropsychological
studies, too, are inconsistent (Goldstein and Lewine
2000; Fitzgerald and Seeman, 2000). Goldberg et al.
(1995) for example studied four independent cohorts
of men and women with schizophrenia using a large
test battery, but did not find any substantial neuropsy-
chological gender differences (Albus et al., 1996). Most
authors compared samples that differed in the durations
of their illness.
To compare clinical subtypes we analysed
symptomatology, type of illness onset and course from
the first sign to the climax of the first episode. The
three types of onset: acute, subacute and chronic and
three categories of initial symptoms: positive, negative
and unspecific, did not show any significant gender
Table 1 Comparison of clinical and operationalised diagnoses
and CATEGO subclasses, scores and index of definition at
first admission (= in the first psychotic episode) between men
and women – ABC study sample of 232 first-episode cases
(= 84% of 276 first admissions)
Diagnosis (%)* females males p
n=124 n=108
Schizophrenia broad definition 100% 100%
(ICD-9: 295, 297, 298.3/4)
Schizophrenia ICD 295 87.1% 88.0% n.s
Operationalised diagnosis:
CATEGO ICD 295 79.0% 73.1% n.s
CATEGO class S+ 73.4% 67.6% n.s
CATEGO: affective psychosis 13.7% 13.0% n.s
Scores (mean values)**
PSE: Index of definition 7.47 7.49 n.s
CATEGO: total score 40.67 41.44 n.s
CATEGO subscores:
DAH (delusions, hallucinations) 10.83 10.01 n.s
BSO (behaviour, speech) 8.04 7.85 n.s
SNR (specific neurotic syndrome) 7.11 7.68 n.s
NSN (non-specific neurotic syndrome) 14.69 15.91 n.s
* chi2-tests
** t-tests
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Table 2  Percentages of men and women presenting the ten
most frequent earliest signs of schizophrenia reported by the
patients1 – ABC first-episode sample n=232
Total Men Women p
(n=232) (n=108) (n=124)
% % %
Restlessness 19 15 22
Depression 19 15 22
Anxiety 18 17 19
Trouble with thinking
and concentration 16 19 14
Worrying 15 9 20 *
Lack of self-confidence 13 10 15
Lack of energy, slowness 12 8 15
Poor work performance 11 12 10
Social withdrawal,
distrust 10 8 12
Social withdrawal,
communication 10 8 12
1 Based on closed questions in the IRAOS interview, multiple
counting possible.
All items tested for sex differences; *: p £ 0.05
Source: Häfner et al., 1995, modified.
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differences (Table 3). Nor did the six symptom clusters
– representing empirical subtypes – derived from the
psychotic prephase of a mean duration of 1.3 years –
differ significantly between men and women either in
mean age of onset or in frequency (Table 4).
These findings indicate that the proxy characteristics
of schizophrenia – symptoms, psychopathological
subtypes, types of onset and early illness course – show
no major differences between men and women.
Accounting for this result maybe the homogeneous stage
of illness (first psychotic episode), representativeness,
size and the wide age range of 12 to 59 years of the
sample. This result provides support for the assumption
that the inconsistency in the literature might be a result
of methodological shortcomings rather than a reflection of
true gender differences.
The interaction of symptom presentation and
gender with age – a frequent further source for error in
comparative studies – was not taken into account in
this first analysis, based on mean values of the total age
of risk range of 12 to 59 years in both sexes. Focusing
on the validity of the findings, Jablensky (1995)
summed up the results reported in the literature on sex
differences in the symptom expression of schizophrenia
as follows: “There is no unequivocal evidence of
consistent sex differences in the symptom profiles of
schizophrenia and particularly in the frequency of
positive and negative symptoms”.
Table 3 Type of onset and type of initial symptoms of schizophrenia – ABC first-episode sample n=232
Total Men Women
n=232 n=108 n=124
Type of onset*
Acute
(£ 1 month) 18% 19% 17%
Subacute
(> 1 month £ 1 year) 15% 11% 18%
Insidious or chronic 68% 70% 65%
(> 1 year)
Type of first symptoms*
Negative or non-specific 73% 70% 76%
Positive  7%  7%  6%
Both 20% 22% 19%
* The variables listed, except “worrying”, showed no significant sex differences.
Source: Häfner et al., 1995, modified.
Table 4 Age at first admission and frequency of symptom clusters in the psychotic prephase (from first positive symptom to
first admission) of the first psychotic episode in men and women with schizophrenia
Cluster Non-specific, Delusional Psychotic thought Auditory Disorganisation/ Low values on
negative, depressive disorder hallucinations, psycotic thought all dimensions
substance abuse disorder
Sex:
males (%) 49.2 45.2 40.6 48.4 50.0 42.3
females (%) 50.8 54.8 59.4 51.6 50.0 57.7
Chi2 = 1.1, df: 5;
p=0.95
Age at first 31.1 29.8 29.9 29.3 30.3 31.4
admission (years)
(both sexes)
F=0.293, df=5;
p=0.91
Source: Häfner, 2000.
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Gender difference in the morbid risk (Domain 2)
The male-female ratio of the incidence rates and
lifetime risk of schizophrenia varies considerably in the
literature. According to Hambrecht et al. (1994) the
male-female ratio of annual incidence rates ranges from
0.70 to 3.47/10,000 population. Because of the
unevenness of the male and female age distributions in
the numerator (e.g. late-onset in women) and the
denominator (e.g. population at risk) it is very difficult
to calculate sex-specific risks correctly. The male
predominance in the majority of the studies (Lewine,
1988; Castle et al., 1993; Goldstein and Lewine, 2000;
see also Häfner and an der Heiden, 1997) are accounted
for by an overrepresentation of young males and an
underrepresentation of female late-onset cases in many
of the samples studied, particularly those with age cut-
offs of 45 (DSM-III) (Iacono and Beiser, 1992). Other
limitations are small catchment areas, small and/or non-
representative populations, restricted diagnostic or
screening criteria, non-use of standardised assessment
techniques (Hambrecht et al., 1992).
The rare studies which try to avoid these
methodological pitfalls show a trend towards
convergence in the male-female lifetime prevalence rates
for schizophrenia of a broad, but sufficiently precise
diagnostic definition (e.g. Jablensky et al., 1992; Häfner
and an der Heiden, 1997). But the same does not apply
to rates based on diagnoses requiring a 6-month
symptom persistence or social decline prior to first
contact, as for example do DSM-III-R and – IV
diagnoses of schizophrenia (APA, 1987; 1994). In
addition, it is not clear whether the rates would converge
if schizophrenia-like delusional disorders of old age (late
paraphrenia etc.), which show markedly higher
incidence rates for women, were included (Castle and
Murray 1993; van Os et al., 1995; Häfner et al., 2001b).
We calculated cumulative incidence rates – a good
indicator of the lifetime risk – as based on five-year age
bands of the population studied, from age band 12 to
14 years to age band 54 to 59 years at first admission.
As figure 2 shows, men consumed their lifetime risk
until age-band 30 to 35 years more rapidly than women
did. From that age on, however, women caught up with
men, finally reaching almost the same lifetime rate at
about 13/100,000. The shape of the curves also clearly
shows that lower age cut-offs are bound to lead to a
male predominance in the risk ratios. This result provided
further support for the hypothesis that the disorder as
such is essentially the same in men and women.
1) Npop = total population
2) n = number of patients in 2 years
Source of data: a representative first-admission sample (1987/89) n=392
Catchment area: Mannheim, Heidelberg, Rhine-Neckar-District, Eastern Palatinate
Figure 2  Cumulative incidence rates for schizophrenia, broad definition (ICD 295, 297, 298.3 and .4).
Source: Häfner et al., 1991.
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Childhood and youth antecedents of schizophrenia
(Domain 3)
Normal early childhood development (Richman et
al., 1982; Earls, 1987) differs very little between the
sexes. In late childhood, boys exhibit more externalising
behaviours and a slightly higher frequency of attention
deficits and girls more anxiety (Anderson et al., 1987;
Campball, 1990; Cohen et al., 1993; Gomez et al., 1999).
From puberty on, the mental health risks of males and
females follow different lines, males showing a greater
frequency of hyperactivity, attention deficit disorder,
dissocial behaviour, aggressiveness and antisocial
personality disorder and females a greater frequency of
anxiety and affective disorders. Rosenfield (2000)
distinguished between externalising disorders including
antisocial behaviour and substance abuse, more frequent
in men, and internalising disorder including anxiety and
depression, more frequent in women. These different
age- and sex- specific behavioural trends have to be
taken into account in schizophrenia, too.
As shown in studies based on teachers, ‘and
parents’ reports (Watt et al., 1984), on offpsring of
schizophrenic mothers (Erlenmeyer-Kimling et al., 1993;
Cannon et al., 1993, Cannon & Mednick, 1993; Parnas
et al., 1993), on two British (Jones et al., 1995) and
one North-Finnish (Isohanni et al., 1998a, b) population
birth cohort, adult-onset schizophrenia is preceded by
mild neuromotor, cognitive and behavioural anomalies.
The minor early-childhood deficits in neuromotor
and speech development as antecedents of schizophrenia
seem to occur at the same frequency in boys and girls.
From school age on behavioural anomalies manifest
themselves several years later in girls than in boys (Crow
et al., 1995). These anomalies are particularly severe in
children of mothers with schizophrenia, boys clearly
scoring higher than girls on cognitive impairment
(Erlenmeyer-Kimling et al., 1984; Castle, 2000). Walker
et al. (1995) compared private childhood video clips of
siblings discordant for schizophrenia. They also showed
that premorbid behavioural signs manifest themselves
somewhat later in girls than in boys (Figure 3). But,
similarly to the behavioural patterns of normal children,
boys exhibit primarily externalising behaviours (e.g.
hyperactivity, physical and verbal aggression, failure of
behavioural inhibition), whereas girls manifest mainly
“internalising” behaviours, e.g. shyness, social
withdrawal, depressive mood and social anxiety.
Promorbid functioning (Domain 4)
Follow-back studies of school records, retros-
pective studies with patients and prospective studies of
children of mothers suffering from schizophrenia have
consistently found a greater frequency of premorbid
deficits in social and occupational functioning for men
than women (McGlashan and Bardenstein, 1990; Mueser
et al., 1990a; Moldin, 2000). This was also shown by
Figure 3  Antecedents of schizophrenia in childhood and youth: comparison of pre-schizophrenic and control siblings, mean externalized/
internalized behaviour problem scores by age period and sex.
Source: Walker et al., 1995, modified.
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the Israeli conscript study among probands aged 16 to
17 years (Weiser et al., 2000). In view of the normal
behavioural gender differences in childhood and
adolescence and the three to four years later onset of the
prodromal stage of several years’ duration in women
(Häfner et al., 1993a; 1999b) the question arises when
these premorbid dysfunctions come about and end. It is
a fact that numerous studies in which illness onset was
defined by first admission, first contact or psychosis
onset have found gender differences in premorbid
functioning that have been contaminated with the
prodromal stage of the disorder. The prodrome,
characterised by negative symptoms, functional
impairment and social disability, has an earlier onset in
men. The overlap between premorbid dysfunctioning and
the prodromal stage should not be ignored (Castle, 2000).
It is also conceivable that the normal behavioural
differences between males and females discussed above
translate into the differences in premorbid social
functioning.
The gender difference in age at onset and its
consequences (Domain 5)
The gender difference in age at first admission,
which, as mentioned at the outset, was already known
to Kraepelin, is a hallmark of the disorder, as Lewine
(1980), Seeman (1982), Angermeyer and Kühn (1988)
and others have pointed out. Underlying this difference
seems to be an analogous difference in age at illness
onset (Häfner et al. 1995). The pooled data of the World
Health Organization ten-country “Determinants of
Outcome” study (Jablensky et al., 1992) revealed a 3.4
years higher mean age of onset for women than men
(Hambrecht et al., 1994).
In the ABC first-episode sample with a broad
definition of schizophrenia, illness onset and the
consecutive milestones of the early course were dated
by means of the IRAOS interview conducted with the
patients, their relatives and applied to available records
(Häfner et al., 1992; 1999a). Mean age at the
emergence of the first sign of the disorder, first
negative and first positive symptom and at the climax
of the first episode – defined by the maximum of
positive symptoms – ranged from 22.5 to 28.2 years
for males (Figure 4). Women’s mean age at all these
milestones, ranging from 25.4 to 32.2 years, was 2.9
to 4.0 years higher than that of men‘s. As a result, it
seems well established that the disorder manifests itself
clearly later in women than men.
Looking at the distribution of onsets in five-year
age bands over the entire age range, we found an early
and steep increase with a maximum between 15 and 25
years for men and after that a monotonous decrease to
a very low level (Figure 5). In women the rate of onsets
rose slightly less steeply and reached a lower and broader
peak in age band 15 to 30 years. After a decline female
onsets reached a second, somewhat smaller peak in
age group 45 to 50 years around premenopause with a
significant difference to men. The same pattern also
emerged in Castle et al.’s (1993) study, based on the
Camberwell case register, and in our analysis of all first
admissions for a diagnosis of schizophrenia from the
Danish case register (Löffler et al., 1994).
A few studies have failed to find any gender
difference in age at onset. Three studies conducted in
India and based on service utilisation samples (Eaton et
al., 1995, Murthy et al., 1998, Gangadhar et al. 2002)
and a Japanese study (Shimizu et al., 1988) found no
significant gender difference in age at onset, nor did a
case-register study in Croatia (Folnegovic and
Folnegovic-Smalc, 1994) in a sample of 679 patients.
In the Indian and Japanese samples culture-dependent
and age-specific utilisations of psychiaric services
probably have influenced the result. In the Croatian study
emigration waves of primarily young men had swept
over the catchment area (Folnegovic and Folnegovic-
Smalc, 1994), and they might have affected the age
and sex distribution of the population at risk. Addington
et al.‘s study (1996) of 113 patients in Canada, in which,
too, no age difference was found, might have been
biased by the exclusion of older age groups, in which
women with schizophrenia are overrepresented.
Testing the oestrogen hypothesis at different levels
(Domain 5)
The age distribution of onsets in women suggested
an explanation by oestrogen secretion across the female
life-cycle. A protective effect of oestrogen had previously
been suggested by Mendelson et al. (1977), Seeman
(1981), Loranger (1984), Häfner (1987), Lewine
(1988), and Seeman (1996). A neuroleptic-like effect
of short-term oestrogen applications in animals had been
shown by DiPaolo and Falardieu (1985), Fields and
Gordon (1982) and Hruska (1986).
As mentioned at the outset, the design of the animal
experiments for testing the oestrogen hypotheses was
planned with Wagner Gattaz: after a four-week oestrogen
treatment of ovariectomised rats we found a significant
attenuation of apomorphine-stimulated dopaminergic
behaviour compared with two control groups (the one
sterilised and with placebo treatment, the other sham-
operated and with placebo treatment). In a post-mortem
Rev. Psiq. Clín. 29 (6):267-292, 2002Häfner, H.
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Figure 4  Mean age values at five definitions of onset until first admission, first-episode sample of schizophrenia, broad definition
(n=232). Source: Häfner, 1996.
Figure 5  Distribution of age at onset of schizophrenia (first ever sign of mental disorder) by sex, ICD 9: 295, 297, 298.3 and .4), ABC
Schizophrenia Study.
Source: Häfner et al., 1993b.
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analysis we could demonstrate that oestrogen reduces
the sensitivity of D2 receptors (Gattaz et al., 1992). This
effect seems to be responsible for the suppression or
lower probability of symptom production. The effects
were at their highest in young animals.
A decade of experimental oestrogen studies has
shown that the sex hormone has potent neuromodulatory
effects and beneficial functions in both health and disease
(Kulkarni and Fink, 2000). The basic neurobiological
mechanisms include genomic and nongenomic effects
as well as interactions with free radical detoxifying
systems and the inhibition of the cellular liquid
peroxidation (McEwen et al., 1981, Woolley and McEwen,
1994, Sumner and Fink, 1995, Shughrue et al., 1997,
Fink et al., 1998, Sumner et al., 1999, Behl, 2002). The
protective effect in schizophrenia, as shown in our study,
is based on a sensitivity reducing effect on central D2
receptors and the inducement of a significant increase in
5HT3A receptors and a serotonine transporter (SERT).
The reduction of D2 sensitivity is presumably responsible
for attenuating positive symptoms, and the increase in 5HT2A
receptors might protect against depressive and negative
symptoms (Fink, 1995).
Oestrogen also acts receptor independently as a
potent neuroprotective factor. Acting on various sites
of the brain, especially the basic forebrain, the
hypothalamus, but also the spinal cord, oestrogen seems
to improve synaptic connectivity, neurotrophic
signalling, dendritic plasticity and cholinergic activity
(Fink, 1995). Via these mechanisms oestrogen is capable
of improving cognitive functioning and memory not
only at the early stages of Alzheimer’s disease, but also
throughout life. Whether this neuroprotective property
of oestrogen could also be harnessed for preventive or
restitutive purposes in schizophrenia is not yet known.
The applicability of the results of our animal
experiments to human schizophrenia was shown by
Riecher-Rössler et al. (1994a, b). Comparing 32 women
with schizophrenic and 29 women with depressive
episodes, both with normal menstrual cycles, we found
significant negative correlations of increasing oestrogen
plasma levels with schizophrenia symptom scores in
both groups of women, but no correlation with
depressive symptom scores in either group. From this
we concluded that oestrogen also has a weak
neuroleptic-like effect on schizophrenic symptoms. An
analogous variation in symptom severity over the
menstrual cycle was also reported by Hallonquist et al.
(1993), and similar clinical observations had previously
been published by Dalton (1959) and Endo et al. (1978).
Seeman and Cohen (1999), early proponents of
the oestrogen hypothesis, tested the hypothesis that an
earlier onset of functional oestrogen secretion with
puberty might be associated with a later onset of
schizophrenia in women. In line with the hypothesis,
they found a significantly negative correlation between
age at puberty and age at schizophrenia onset in women,
but no correlation in men.
Age difference in severity of illness between men and
women (interaction of age and gender) (Domain 5)
Assuming that a greater severity of illness is
associated with an early outbreak of the illness, men,
lacking the protective effect of oestrogen, would be
expected to develop the most severe forms of the
disorder fairly early and, with increasing age,
increasingly milder forms. In women, as long as
oestrogen remains effective, the disease should be
slightly milder, and a certain proportion of schizophrenias
should not become manifest until menopause. From
premenopause on, with decreasing oestrogen secretion,
women should not only show higher incidence rates,
as depicted in table 5, but also present more severe
forms of the disorder.
A comparison of PSE-CATEGO symptom scores
in early- and late-onset schizophrenia (age at onset 20
years or younger versus 40 years or older) by gender
yielded different age trends for men and women (Table 6).
Four out of eight symptom scores were significantly
lower for late-onset men than for their early-onset
counterparts. In contrast, in late-onset women not a single
symptom score was significantly lower and one, the
SANS global score denoting negative symptomatology,
was significantly higher compared with early-onset cases.
This means that the milder symptomatology of late-onset
schizophrenia is accounted for by men alone. These
gender-different age trends in the severity of first
psychotic episodes support our hypothesis of an age-
dependent protective effect of oestrogen: men develop
relatively severe first episodes at young age, whereas
young women present slightly milder cases on average.
But later in life, severity of first episodes decreases in
men and increases slightly in postmenopausal women.
In clear agreement with our results at the symptom
level, Lewine et al. (1997), who studied the interaction
of sex and age of onset of schizophrenia, found a worse
cognitive outcome for early-onset males (<25 years)
compared with late-onset males and a poorer outcome
for late-onset females compared with early-onset females.
Also in line with our hypothesis are the results of
several long-term studies showing that schizophrenia of
an early onset, too, has a poorer outcome from menopause
on in women than in men (Opjordsmoen, 1991).
Rev. Psiq. Clín. 29 (6):267-292, 2002Häfner, H.
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The antagonism between the strength of
predisposition to the illness and the protective
effect of oestrogen (Domain 5)
Leboyer et al. (1992), DeLisi et al. (1994), Kendler
and Walsh (1995) and Albus & Maier (1995) showed
that there is no major gender difference in age at onset
in familial schizophrenia. In contrast, the definitely non-
familial cases of Albus and Maier’s sample had a gender
difference as pronounced as 5.7 years. In our replication
study of the ABC first-episode sample the gender
difference in age at psychosis onset did indeed fall in
cases with at least one first-degree relative with
schizophrenia from 4.2 in the total sample to 1.6 years
and, thus, below the level of signifigance (Könnecke et
al., 2000) (Figure 6). In sporadic cases (i.e. proband
has no relative with any type of mental disorder) the
gender difference was a highly significant 4.9 years.
As predicted by the oestrogen hypothesis, the age at
onset difference between familial and non-familial cases
was almost entirely limited to women, whereas men
showed no significant difference in age at onset between
familial and non-familial cases.
These results supported Albus & Maier’s
hypothesis: the stronger the patients‘ genetic liability,
the weaker the effect of delay that oestrogen has on
schizophrenia onset (Albus and Maier, 1995).
We then tested whether the other risk factor of
aetiological relevance for schizophrenia, pre- and
perinatal complications, too, weakens the protective
effect of oestrogen. And it indeed does, though to a
somewhat smaller extent than familial load (Figure 7).
Hence, oestrogen is capable of warding off schizo-
phrenia onset the more strongly, the weaker individuals’
vulnerability or strength of predisposition.
Support for the oestrogen hypothesis from
intervention studies (Domain 5)
Reliable evidence for causal effects can be obtained
from intervention studies varying the presumed causal
factors. Kulkarni et al. (1999), conducting a systematic
study with two different dosages of oestradiol as an
adjunct to neuroleptic medication in psychosis, found
significant dose-related improvement in positive and
Table 5 Onset of schizophrenia by age and sex – ABC first-episode sample n=232
Age at first n Men Women m/f
psychotic ratio
symptom
12 - 20 yrs. 49  57%  43% 1.33
21 - 35 136  48%  52% 0.92
36 - 59 47  32%  68% 0.47*
* Odds ratio = 2.16 (sex ratio in the age group against the sex
ratio in the remaining age groups); p < .05
m/f = male/female
Source: Häfner and Nowotny, 1995.
Table 6 Symptomatology at onset: young and old in comparison (age at first psychotic symptom < 21 years vs. > 40 years)
Men Women
Symptomatology Young Vs. Old Young Vs. Old
n=28 Wilcoxon n=9 n=21 Wilcoxon n=24
DAS 12.1 .02* ¯5.7 10.0 .95 10.5
BSO 8.6 .29 7.3 8.9 .44 7.9
SNR 10.7 .11 7.3 8.2 .42 7.1
NSN 18.9 .03* ¯11.4 13.0 .58 13.8
Total score 50.3 .02* ¯31.8 40.0 .80 39.2
SANS 9.3 .29 6.6 6.7 .08t ­9.5
PIRS 10.7 .29 8.4 9.8 .73 10.5
DAS-M 3.0 .06t ¯1.8 1.9 .61 1.8
Source: Häfner et al., 1998a.
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Premorbid hypooestrogenism (Domain 4)
In a historical review Riecher-Rössler and Häfner
(1993) showed that the early psychiatric writers, for
example E. Kraepelin and E. Kretschmer, had already
noticed that persons with schizophrenia show deficits
in the maturation of primary and secondary sex
characteristics more frequently than their healthy peers.
Figure 6  Age at first psychotic symptom by gender and familial load (ABC first-episode sample n=232).
Source: Könnecke et al., 2000.
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negative symptoms (Kulkarni et al., 1999). In two pilot
studies, one with male patients suffering from
schizophrenia, Kulkarni et al. (1996a, b, 2002) also found
significant short-term antipsychotic effects of
adjunctive oestradiol treatment. Improvement in
psychotic symptoms has also been reported to occur
with the addition of a combined oestrogen-progesterone
oral contraceptive (Felthous et al., 1980).
28,6
27 27
31,9
20
22
24
26
28
30
32
34
men women
familial load for
schizophrenia
no familial load
n=125 (60 men, 65 women)
n=26 (7 men, 19 women)
t p < 0.1
p < 0.05*
** p < 0.01
protective oestrogen effect
diminished oestrogen effect
**
*
24,4
25,3
23,8
29,2
15
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21
23
25
27
29
31
33
men women
PPCs certain/presumed
no PPCs
n=65 (35 men, 30 women)
n=22 (12 men, 10 women)
t t
t p < 0.1
*
** p < 0.01
p < 0.05
protective oestrogen effect
diminished oestrogen effect
Figure 7  Age at first psychotic symptom by gender and presence/absence of pre- and perinatal complications (PPC) (ABC first-episode
subsample n=87).
Source: Könnecke et al., 2000.
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As a consequence, it was also early speculated that the
risk for schizophrenia might be associated with gonadal
hypofunctioning. Recently, several authors have fairly
consistently reported subnormal oestrogen blood levels
in women with first-onset schizophrenia not yet treated
with psychotropic drugs (Riecher-Rössler, 2002). The
temptation is now great to regard gonadal hypofunction
as a risk factor amenable to preventive action. But we
are still a long way off from this goal, especially since
the specificity and positive predictive power of
hypooestrogenism for schizophrenia onset have not yet
been demonstrated and are presumably rather low. Under
these circumstances they do not justify any intervention
involving risks.
An unresolved question is whether the finding
might be attributable to secondary, environmental,
causes at least to some extent: The early deficits in
communicability and mating behaviour of pre-
schizophrenic individuals presumably result in a lower
stimulation of the gonadal function due to a sexually
less stimulating environment. Last but not least, the equal
lifetime risk of men and women for schizophrenia hardly
speaks for a lifetime risk factor specific to the female
gender. Nothing is known yet on hypogonadism as a
risk factor for schizophrenia in men.
Abnormalities in brain development and morphology
(Domain 9)
The female brain maturates more rapidly than the
male brain. Hence, it might be less vulnerable to pre-
and perinatal and childhood insults. Castle and Murray
(1991) assumed that the gender difference in age at
onset might be caused by a preponderance of men with
pre- and perinatal complications and an early illness
onset. This hypothesis did not find support in
methodologically sound studies (Geddes and Lawrie,
1995; Jones et al., 1998; Könnecke et al., 2000).
Castle (2000) explains the female preponderance
of schizophrenia and delusional disorders of old age
with a difference in the aging of male and female brains.
According to him the loss of dopamine receptors in
women begins earlier in life, but shows a relative excess
compared with men in later life. This differential process
of loss of D2 receptors might also account for the higher
frequency of tardive dyskinesia in elderly women after
a lengthy treatment with neuroleptics.
We do not know yet whether the sex differences
in brain maturation cause substantial differences in
disease variables in a stricter sense. At any rate the sex-
specific behavioural patterns which become evident in
childhood and youth, for example the highly different
social behaviour, have very different impacts on illness
behaviour and social outcome in male and female patients.
Castle (2000) puts this as follows: “... understanding
differences between women and men in terms of
biological, psychological and social domains can inform
our understanding of gender differences in schizophrenia,
but more broadly schizophrenia as a disorder.” Gender
differences in cognitive functioning of the mature brain
seem to play a minor role in schizophrenia (cf. P. 5;
Goldberg et al., 1995). The basis in brain morphology
is a greater bihemispheric presentation of functions in
female and a more pronounced lateralisation in males
(McGlone, 1980; Witelson, 1989). Crow (1994) took
the gender differences in cerebral lateralisation as a basis
for speculations: a delay in maturation and an increase
in brain size evolved the capacity for a high degree of
communication and social interaction. Schizophrenia is
seen by Crow as a defect of cerebral lateralisation tied
to the emergence of language: “Schizophrenia is the
price (humans) pay for language. The sex difference in
the rate of hemispheric differentiation could account
for the sex difference in age at onset...”. But these are
just hypotheses of minor plausibility still awaiting to be
validated.
A series of neuroanatomical and neuroimaging
studies on gender differences in structural brain
abnormalities have shown more pathology in male than
female patients (Andreasen et al., 1990; Bogerts et al.,
1990; Castle and Murray, 1991; Lewine and Seeman,
1995; Goldstein, 1996). But there are also several studies
that have found no exaggeration of the normal gender
dimorphism of the brain in schizophrenia (Flaum et al.,
1995). The reasons for this inconsistency may have
something to do with the methodologies of these studies
(Goldstein, 1993; 1995a, b; Lauriello et al., 1997;
Goldstein and Lewine, 2000), with the small sample
sizes in particular (Moldin, 2000). For example, sMRI
studies have reported a preponderance of enlarged lateral
ventricles (Andreasen et al. 1990) and a small
hippocampal formation in males (Bogerts et al., 1990).
A post-mortem study (Crow et al., 1989) found a larger
planum temporale in male but not in female patients
with schizophrenia. A few studies have reported
ventricular enlargement in women, but not in men
(Nasrallah et al., 1990; Gur et al., 1991). Despite
increasing controlling for confounding factors, like IQ,
ethnicity and social class, it is still too early to pass a
definitive judgement on the role of these factors.
But comparative analysis based on functional
imaging (e.g. Gur and Gur, 1990; Gur et al., 1995) and
neurophysiological paradigms (EP etc., Reite et al., 1989;
1993), have equally failed to provide a definitive answer
to sex differences in schizophrenia. For this reason
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especially the case on the effects of steroid hormones
on brain development and brain functioning and their
implications for the risk of schizophrenia (Seeman,
1989a; Seeman and Lang, 1990; Behl, 2002) cannot be
closed yet.
Gender differences in illness behaviour (Domain 6)
The “normal” sex differences in social and coping
behaviour in adolescence and early adulthood led us to
investigate them in schizophrenia, too. To analyse sex
differences in the first illness episode in greater detail
we compared all the 303 single items from the
instruments we used for measuring symptoms,
functional impairment and social disability (PSE, SANS,
PIRS, DAS and IRAOS) in the first episode. Controlling
for multiple testing we found no significant gender
differences in the positive and negative core symptoms,
except for some contents of delusions, such as delusions
of pregnancy, which were – quite understandably –
more frequent in women.
The most pronounced gender difference emerged
with socially adverse behavioural items, such as self-
neglect, reduced interest in a job, social withdrawal and
deficits of communication, which were all significantly
more frequent in men in the first psychotic episode
(Table 7). Only one – socially favourable – behavioural
item was significantly more frequent in women:
overadaptiveness/conformity. The cumulative prevalence
of drug and alcohol abuse, too, was significantly more
frequent in men, as shown by several other studies
(Mueser et al., 1990b, 1992; Soyka, 1994; Kessler et
al., 1994; Jenkins et al., 1997; Kandel, 2000).
Restlessness was the only further item that showed a
significantly higher frequency in women.
But these findings are presumably not specific to
schizophrenia, considering the behavioural gender
differences in normal development mentioned above.
In view of the consistent reports of a higher frequency
of conduct disorders, disruptive, antisocial and violent
behaviour and of alcohol and substance abuse among
young men in comparison with their female counterparts
from population studies (Choquet and Ledoux, 1994;
Döpfner et al., 1997), we are here probably dealing
with a reflection of normal gender- and age-specific
behaviour. The normal psychology of behavioural
gender differences, reviewed for example by Maccoby
and Jacklin (1974), has shown that boys and young
men exhibit a higher frequency of aggressive behaviour,
in particular antisocial aggression, than girls and young
women do, who display more prosocial aggression or
aggressive inhibition and a greater acceptance of
authority.
But this socially adverse illness behaviour of men
with schizophrenia is strongly age-dependent, showing
the highest frequency before age 30 (Figure 8). With
increasing age men’s illness behaviour in schizophrenia
becomes socially more favourable indicating improved
adjustment and, as a result, probably also reducing the
male disadvantage in the social course of schizophrenia.
Table 7 Behavioural items with significant sex differences (from a total of 303 PSE, PIRS, SANS, DAS and IRAOS items)* –
ABC first-episode sample, n=232
More frequent in women: More frequent in men:
a) cumulative until first admission
n restlessness n drug abuse
n alcohol abuse
b) cross-sectional: at first admission
n overadaptiveness/ n self-neglect
conformity n reduced interest in a job
n social inattentiveness
n deficits of free time activities
n deficits of communication
n social disability (overall estimate)
n loss of interests
n deficits of personal hygiene
* Validated by split-half method for Â-correction
Source: Häfner, 1998.
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Sex differences in the course and outcome of
schizophrenia (Domain 7)
A wealth of studies have reported a poorer short-
and medium-term course of schizophrenia for male
compared with female patients. In a review of mainly
short- and medium-term follow-up studies Angermeyer
et al. (1990) found that about half of the studies showed
a more favourable outcome in women, and this finding
was statistically significant. When the dimensions of
illness course and outcome have been looked at
separately, the difference has turned out to be accounted
for by the social and not the symptom-related course
(Biehl et al., 1986; Salokangas et al., 1987; Häfner et
al., 1999b).
In our study the symptom-related course over 5
years after first admission indeed showed no significant
difference between men and women either in the
CATEGO global scores or in the four subscores
(Figure 9). The mean symptom scores from remission
of the first episode on indicated, rather than a trend to
deterioration, absence of any significant change over
time. By contrast, the social course of the disorder,
indicated by the behavioural items with significant sex
differences at first admission (cf. Table 7), was
significantly poorer for men throughout the 5-year
follow-up period studied (Figure 10). The same was
true with social disability measured by the DAS (WHO,
1988). This result lends support to our hypothesis that
men’s socially unfavourable illness behaviour might
contribute to their poorer social course and outcome,
whereas women’s higher tendency to prosocial
behaviour, cooperativeness and compliance might
influence the social course of schizophrenia favourably.
Real-life disadvantages are caused by deficits in
social functioning. This leads to the question when and
to what extent social disability, whatever its causes,
emerges in the course of the disorder. We traced
dysfunctional social roles and dysfunctional overall
behaviour by means of the Disability Assessment
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Mean score
4.1
4.4
4.2
4.0
3.8
3.6
3.4
3.2
3.0
3.6
3.4
Age at first admission 12-20 years 21-35 years 36-59 years
* Self-neglect; Deficits of free time activities; Deficits of communication
Reduced interest in a job; social disability (overall estimate); loss of interests;
Deficits in person al hygiene, social inattentiveness.
Figure 8  Socially negative behaviour* of men (significantly different to women's) at first admission by age (ABC first-episode sample
n=232).
Source: Häfner, 2000.
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Figure 10  Socially negative behaviour over five years after first admission for schizophrenia by sex (ABC first-episode follow-up
subsample n=115).
Source: Häfner et al., 1998b.
Figure 9  Five-year course of schizophrenia (from first admission – 6 cross sections) for men and women by the CATEGO total score
(ABC first-episode follow-up subsample n=115).
Source: Häfner, 1998.
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Schedule (WHO, 1988) retrospectively from first
admission back. As figure 11 shows, the disabilities
measured by the DAS items – dysfunctional social roles
and behaviours – manifested themselves on average as
early as 2 to 4 years before first admission. Hence, it
was long before the first psychiatric contact that the
patients with schizophrenia first exhibited deficits in
social functioning.
For a reliable assessment of the social course and
consequences of a disorder it is necessary to proceed
from a baseline, the level of social development at the
onset of the disorder. We chose six key social roles
characteristic of the main period of risk for schizophrenia
and compared them at age of illness onset in three age
groups: 20 or younger, 21 to 35 years and 36 and older.
The finding was trivial: large, significant age-differences
in the six roles studied, i.e. school education,
occupational training, employment, own income, own
accommodation, marriage or stable partnership. These
roles indicate the level of social development at illness
onset: the older at onset, the higher the social status.
A comparison of social-role performance, as based
on these six indicative roles, at illness onset between
male and female patients revealed significant advantages
for women in the domains of employment, own income
and marriage or stable partnership in particular (Table 8).
From these results we inferred that due to the disorder’s
three to four years earlier intrusion in men’s social
biographies it might be their lower baseline of social
development at illness onset and their socially adverse
illness behaviour that explain their more unfavourable
social course compared with women’s.
To demonstrate how schizophrenia affects social
development between illness onset and first admission
in men and women, we chose the most vulnerable social
role: marriage or stable partnership. We compared 57
first-episode cases of schizophrenia from Mannheim
with 57 controls matched for age-, sex- and place of
residence. At illness onset there was no significant
difference between patients and healthy controls, male
or female (Figure 12). But, because of the age
difference of 4 years and men’s 2.5 years higher age of
marrying in the general population at that time males
and females showed a significant difference: during the
period of 6 years the percentage of healthy men married
or in a stable partnership gradually approached that of
healthy women, whereas the figures for men and
women with schizophrenia fell continuously after illness
Figure 11  Onset of social disabilities (months before index admission).
Source: Häfner et al., 1996, modified.
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Table 8 Social “baseline” at illness onset: social-role performance of men and women at the emergence of the first sign of mental
disorder – ABC first-episode sample n=232
Men Women Total
n=108 n=124 n=232
Age (in years) 22.5 25.4 24.0
% % %
School education 70 69 70
Occupational training 41 n.s. 38 39
Employment 37 * 52 45
Own income 44 n.s. 55 50
Own accommodation 39 * 54 47
Marriage or stable
partnership 28 ** 52 41
tp ≤ 0.1; * p ≤ 0.05; ** p ≤ 0.01; n.s. = not significant
Source: Häfner, 1996, modified
Figure 12  Development of social-role performance in men and women with schizophrenia from illness onset to first admission: marriage
or stable partnership (ABC first-episode sample n=232).
Source: Häfner et al., 1999b.
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onset. Female patients, however, managed to retain their
significant advantage over their male counterparts at
first admission: at that time 33 % of the women with
schizophrenia, but only 17 % of the male patients were
living with a spouse or partner, compared with 78 % of
the female and 60 % of the male controls.
Predicting five-year social outcome (after first
admission) (Domain 7)
The next step was to test the predictive power of
the two main variables of social course and outcome –
level of social development at psychosis onset and
socially adverse illness behaviour at first admission.
Figure 13 illustrates two models: on the right a stepwise
logistic regression including the two index variables and
symptoms at first admission measured by the PSE, type
of onset, age at first psychotic symptom and gender,
and on the left a path-analytic model for analysing
partial correlations of age at onset and gender with the
two social variables. Significant predictors of 5-year
social outcome, operationalised by the ability to earn
one’s living, were the number of non-fulfilled social
roles at psychosis onset and the number of items of
socially adverse illness behaviour at first admission.
Symptomatology and type of onset had no effect, age
and gender merely that mediated by the first two
variables. This is clearly shown in the pathanalytic model
on the left, which revealed highly significant partial
correlations of age at onset and gender with the two
mediating variables: social development at illness
onset and illness behaviour (Häfner et al., 2001b). This
means that the sex difference in the social course of
schizophrenia, instead of reflecting a gender-different
illness, is basically a result of the protective effect of
oestrogen in women, mediated by the higher stage of
social development at illness onset, and an additional
effect of the socially adverse illness behaviour of men.
Sex differences in the long-term course of
schizophrenia (Domain 7)
There are only few methodologically high-standard
follow-up studies of representative first-episode samples
extending over 10 years or more. The studies by an der
Heiden et al. (1995; 1996), Opjordsmoen (1991) and
Goldstein (1988) showed that the gender differences in
the early course of the disorder become diluted over
long periods of follow-up. Harrison et al. (1996) reported
a gender effect in a small first-admission sample
sustained over a 13-year period after adjustment for
sociodemographic variables and type of early course.
The Mannheim first-admission cohort (an der
Heiden et al., 1995; 1996) of the WHO Disability Study
Figure 13  Prediction of five-year social outcome in schizophrenia: analysis of direct and mediating causal factors (ABC first-episode
follow-up subsample n=115).
Source: Häfner et al, 2001b.
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was assessed at 10 cross sections over 15.6 years after
first admission. The repeated single measurements,
based on the PSE total score, demonstrated a relatively
high degree of stability in the mean symptom scores
over the long-term course (Figure 14). But women,
showing significantly lower symptom scores only in
the first 1.5 years after first admission primarily because
of their shorter first episodes, attained the level of male
scores in the long-term. From two to 15.6 years after
first admission men and women showed almost equal
symptom levels.
The gender differences in social disability, still
present at the 5-year assessment after first admission,
had disappeared at the later assessments, possibly as a
result of the age-related decrease in socially negative
male behaviour. During the last nine months before the
15.6-year assessment the percentages of good (no
symptoms or disability present) and poor outcomes
(suffering from at least one positive or negative core
symptom or disability in the last 9 months) – 40% versus
60% – did not show any sex difference, as illustrated in
figure 15.
But two thirds of the symptom-free women and
only one tenth of the symptom-free men continued to
be on antipsychotic drugs. We assume that this gender
difference, too, resulted from sex-specific illness
behaviour: women’s generally better cooperativeness
and compliance with treatment measures compared with
men’s. An alternative interpretation, which we are unable
to refute, runs that men with schizophrenia who are
doing well do not require as much antipsychotic
treatment. The symptomatic group though did not show
any significant gender difference in their use of
neuroleptic drugs.
Inspite of the similar outcome measures in terms
of symptom scores and social disability, there were
considerable differences in marital status between men
and women (Table 9): 71% of the male patients, but
only 23% of the female patients had never married.
Consequently, only 28% of the men, but 53% of the
women were living with a spouse and 28% of the men,
but only 5% of the women were living in a supervised
apartment or home. Naturally, more than twice as many
women as men had children. Interestingly, however,
there was no significant sex difference in employment
status, which coincided with the equal measures of
social disability for men and women.
The fact that women fare better in real life than
men is obviously accounted for by women’s more
favourable social conditions at illness onset and socially
less adverse behaviour in the course of the illness.
However, a high proportion of the female patients who
had married before illness onset or in the subsequent
15-year course of illness were divorced and some had
re-married. It seems that because of their more prosocial
behaviour, presumably in conjunction with the traditional
Figure 14  PSE total score over 15.6 years after first admission (9 cross sections) by sex (first-admission sample of the WHO “Disability
Study” Mannheim cohort n=70).
Source: an der Heiden et al., 1995.
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Response to neuroleptic treatment (Domain 8)
Because of the neuroleptic-like effect of
oestrogen women with schizophrenia appear to
respond more favourably than male patients to
neuroleptics or require lower doses. In addition, post-
menopausal women with their more severe illness
seem to need higher doses of antipsychotic
medications than their male counterparts do, who
present milder illness in this period of age. Seeman
and colleagues first reported this finding in 1983
(Seeman 1983) and have since then presented several
results confirming the initial finding (e.g. Seeman,
1989b; Dickson et al., 2000). But not all the findings
on the topic are consistent. Other carefully designed
studies have failed to find gender differences in daily
antipsychotic doses or treatment efficacy (Jeste et al.,
1996). Moldin (2000) recently concluded that “more
work is needed regarding gender differences ... in
response to new therapeutic compounds”. What seems
to be clear is that men and women require specific
treatment programmes not only because of the
different effects of gonadal hormones, but also
because of the differences in their behavioural
predispositions, psychosocial situations, social course
of the disorder and life courses (Seeman, 1983,
1989b).]
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Figure 15  Two outcome groups 14 years after first admission by sex. Based on data from an der Heiden et al., 1996.
Source: Häfner, 2000.
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Table 9 Living situation of schizophrenic men and women
15.5 years after first admission – WHO “Disability Study”
Mannheim cohort n=70 at inclusion in the study
Women Men
n = 22 n = 34
Mean age+ 44 years 41 years n.s.
Outcome:
symptoms or disability
present 59% 62% n.s.
Living situation:
never married 23% 71% **
married+ 42% 19% t
lives with a spouse/
partner+ 53% 28% *
lives in a home+ 5% 28% t
own children+ 45% 26% *
Employment status:
has a regular job 26% 31% n.s.
n.s.: not significant t: p < 0.1 *: p < 0.05 **: p ≤ 0.001
+n= 51 due to missing data
Source: an der Heiden, 2002
gender roles in society, women with persistent
schizophrenia, more often than their male counterparts,
manage to find a new partner after a failed marriage or
to some extent also to maintain an existing partnership.
Coping with illness (Domain 5)
I. Weber (1996) from our group looked into
cognitive coping with the illness and subjective life
satisfaction in this fairly homogeneous cohort 15.5 years
after first admission by using a life goal and satisfaction
questionnaire (FNL: Fragebogen zur Lebenszielen und
Lebenszufriedenzeit; Kraak and Nord-Rüdiger, 1989),
based on Lehman’s (1983a, b) interaction model. She
assessed subjective importance of life goals, goal
achievement and life domain-specific satisfaction and
found no correlation between symptom measures and
social disability on the one hand and overall life
satisfaction on the other. But patients and controls
showed significant differences: 82% of the control men
and 84% of the control women reported a high degree
of overall life satisfaction, whereas only 43% of the
male and 58% of the female patients did so.
Many life goals were considered only slightly less
important by patients with schizophrenia than by healthy
controls, for example to be loved or to maintain stable
relationships and self-esteem were almost equally
important to both patients and healthy individuals
(Figure 16). But only male patients considered sexual
relationships and employment as important as did healthy
controls. Women had significantly reduced their
expectations in these life domains during the lengthy
course of the disease obviously as a means of coping
with their diminished capacities. As a consequence,
women with schizophrenia were generally more satisfied
than their male counterparts, whose goal achievement
and satisfaction with current status differed more
markedly from their high expectations and from those
of healthy controls. Nonetheless, women managed to
achieve, to a greater extent than male patients, some of
their valued aspirations in the domain of interpersonal
relationships. Again, it was their illness behaviour that
contributed to the more favourable social situation and
to their better coping with illness-related deficits and,
as a result, to their slightly higher life satisfaction
compared with men’s.
Conclusions
The nuclear process of schizophrenia, irrespective
of age effects, does not essentially differ between
men and women. However, due to age-dependent
neurohormonal and normal behavioural gender
Rev. Psiq. Clín. 29 (6):267-292, 2002Häfner, H.
Figure 16  Life-goal importance, achievement and satisfaction of men (n=30) and women (n=18) with schizophrenia15.5 years after first
admission compared with age- and sex-matched controls (first-admission sample of the WHO "Disability Study" Mannheim cohort n= 70).
Based on data from Weber 1996.
Source: Häfner, 2000.
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differences, age as well as stage of social development
at onset, the social course of the disorder and the
severity of illness show considerable differences
across the life-cycle: men fare particularly poorly at
younger age, but significantly better at a later age,
whereas women fare considerably better until the age
of menopause, but worse afterwards. In the long-
term, too, women cope with the illness better and,
as a consequence, have better life satisfaction than
men do. Oestrogen, which is responsible for a major
part of these sex differences via its sensitivity-
reducing effect on central D2 receptors, has meanhwile
also been demonstrated to have therapeutic effects on
both positive and negative symptoms in acute
psychosis.
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